Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas

Blood

Volumn 121, Issue 2, 2013, Pages 351-359

  Gaudio, Eugenio ^a,b   Paduano, Francesco ^b   Ngankeu, Apollinaire ^a   Lovat, Francesca ^a   Fabbri, Muller ^c   Sun, Hui Lung ^a   Gasparini, Pierluigi ^a   Efanov, Alexey ^a   Peng, Yong ^a   Zanesi, Nicola ^a   Shuaib, Mohammed A ^a   Rassenti, Laura Z ^d   Kipps, Thomas J ^d   Li, Chenglong ^e   Aqeilan, Rami I ^a,f   Lesinski, Gregory B ^g   Trapasso, Francesco ^a,b   Croce, Carlo M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; HEAT SHOCK PROTEIN 70; PROTEIN; T CELL LEUKEMIA LYMPHOMA 1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL CHRONIC LYMPHOCYTIC LEUKEMIA; CANCER GROWTH; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; INHIBITION KINETICS; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR XENOGRAFT; UBIQUITINATION; VALIDATION PROCESS;

EID: 84872350919     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-457374     Document Type: Article

References (51)

1. Pekarsky Y, Halas C, Isobe M, Russo G. Croce CM. Abnormalities at 14q32. 1 in T cell malignancies involve two oncogenes. Proc Natl Acad Sci U S A. 1999;96(6):2949-2951. (Pubitemid 29148824)
2. Narducci MG, Fiorenza MT, Kang SM, et al. TCL1 participates in early embryonic development and is overexpressed in human seminomas. Proc Natl Acad Sci U S A. 2002;99(18):11712-11717. (Pubitemid 34994464)
3. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci U S A. 1994;91(26):12530- 12534.
4. Madani A, Choukroun V, Soulier J, et al. Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. Blood. 1996;87(5):1923-1927.
5. Narducci MG, Virgilio L, Engiles JB, et al. The murine Tcl1 oncogene: embryonic and lymphoid cell expression. Oncogene. 1997;15(8):919-926. (Pubitemid 27399553)
6. Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006;66(24):11590-11593. (Pubitemid 46094168)
7. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leucemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U SA. 2002;99(10):6955-60. (Pubitemid 34526239)
8. Yan XJ, Albesiano E, Zanesi N, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2006;103(31):11713-8. (Pubitemid 44182516)
9. Gaudio E, Spizzo R, Paduano F, et al. Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies. Blood. 2012;119(1):180-187.
10. Ropars V, Despouy G, Stern MH, Benichou S, Roumestand C, Arold ST. The TCL1A oncoprotein interacts directly with the NF-KappaB inhibitor IkappaB. PLoS One. 2009;4(8):e6567.
11. Jung M, Kondratyev A, Lee SA, Dimtchev A, Dritschilo A. ATM gene product phosphorylates I kappa B-alpha. Cancer Res. 1997;57(1):24-27. (Pubitemid 27020322)
12. Grosjean-Raillard J, Tailler M, Ades L, et al. ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 2009;28(8):1099- 1109.
13. Shifera AS. Protein-protein interactions involving IKKgamma (NEMO) that promote the activation of NF-kappaB. J Cell Physiol. 2010;223(3):558-261.
14. Thyss R, Virolle V, Imbert V, Peyron JF, Aberdam D, Virolle T. NF-kappaB/Egr-1/Gadd45 are sequentially activated upon UVB irradiation to mediate epidermal cell death. EMBO J. 2005;24(1):128-137. (Pubitemid 40188470)
15. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell. 2008;14(3):250-262.
16. Jaattela M. Heat shock proteins as cellular lifeguards. Ann Med. 1999;31(4):261-271. (Pubitemid 29366608)
17. Garrido C, Brunet M, Didelot C, et a. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle. 2006;5(22):2592-2601.
18. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene. 2004;23(16):2907-2918. (Pubitemid 38638852)
19. Xanthoudakis S, Nicholson DW. Heat-shock proteins as death determinants. Nat Cell Biol. 2000;2(9):E163-165.
20. Brodsky JL, Chiosis G Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators. Curr Top Med Chem. 2006;6(11):1215-1225. (Pubitemid 44110931)
21. Guzhova I, Margulis B. Hsp70 chaperone as a survival factor in cell pathology. Int Rev Cytol. 2006;254:101-149. (Pubitemid 44828728)
22. Schmitt E, Maingret L, Puig PE, et al. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res. 2006;66(8):4191-4197.
23. Leu JI, Pimkina J, Frank A, Murphy ME, George DL. A small molecule inhibitor of inducible heat shock protein 70. Mol Cell. 2009;36(1):15-27.
24. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol. 2007;81(1):15-27. (Pubitemid 46021247)
25. Calderwood SK, Mambula SS, Gray PJ Jr, Theriault JR. Extracellular heat shock proteins in cell signaling. FEBS Lett. 2007;581(19):3689-3694. (Pubitemid 47081004)
26. Barreto A, Gonzales JM, Kabingu E, Fiorentino S. Stress-induced release of HSC70 from human tumors. Cell Immunol. 2003;222(2):97-104. (Pubitemid 36765431)
27. Broquet AH, Thomas G, Masliah J, Trugnan G, Bachelet M. Expression of the molecular chaperone Hsp70 in detergent-resistant microdomains correlates with its membrane delivery and release. J Biol Chem. 2003;278(24):21601-21606. (Pubitemid 36792559)
28. Wei YQ, Zhao X, Kariya Y, Teshigawara K, Uchida A. Inhibition of proliferation and induction of apoptosis by abrogation of heat-shock protein (HSP) 70 expression in tumor cells. Cancer Immunol Immunother. 1995;40(2):73-78.
29. Nylandsted J, Rohde M, Brand K, et al. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc Natl Acad Sci U S A. 2000;97(14):7871-7876. (Pubitemid 30460740)
30. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10(2):86-103. (Pubitemid 40942470)
31. Li G, Xu Y, Guan D, Liu Z, Liu DX. HSP70 protein promotes survival of C6 and U87 glioma cells by inhibition of ATF5 degradation. J Biol Chem. 2011;286(23):20251-20259.
32. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59(2):111-137.
33. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther. 2004;3(8):1021-1030. (Pubitemid 39199597)
34. Parmiani G, Testori A, Maio M, et al. Heat shock proteins and their use as anticancer vaccines. Clin Cancer Res. 2004;10(24):8142-8146. (Pubitemid 40053371)
35. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5(10):761-772. (Pubitemid 41400776)
36. Chiosis G. Discovery and development of purine-scaffold Hsp90 inhibitors. Curr Top Med Chem. 2006;6(11):1183-91. (Pubitemid 44110929)
37. Gurbuxani S, Bruey JM, Fromentin A, et al. Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells. Oncogene. 2001;20(51):7478-7485. (Pubitemid 33086907)
38. Garrido C, Gurbuxani S, Ravagnan L, Kroemer G. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun. 2001;286(3):433-442. (Pubitemid 32912965)
39. Jinwal UK, Miyata Y, Koren J 3rd, et al. Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci. 2009;29(39):12079-12088.
40. Rérole AL, Gobbo J, De Thonel A, et al. Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res. 2011;71(2):484-495.
41. Laine J, Künstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell. 2000;6(2):395-407.
42. Johnson AJ, Wagner AJ, Cheney CM, et al. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol. 2007;139(5):837-844. (Pubitemid 350115739)
43. Koren J 3rd, Jinwal UK, Jin Y, et al. Facilitating Akt clearance via manipulation of Hsp70 activity and levels. J Biol Chem. 2010;285(4):2498-2505.
44. Pekarsky Y, Palamarchuk A, Maximov V, et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A. 2008;105(50):19643-19648.
45. King FW, Wawrzynow A, Höhfeld J, Zylicz M. Cochaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53. EMBO J. 2001;20(22):6297-6305. (Pubitemid 33078703)
46. Zylicz M, King FW, Wawrzynow A. Hsp70 interactions with the p53 tumour suppressor protein. EMBO J. 2001;20(17):4634-4638. (Pubitemid 32848616)
47. Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008;111(1): 328-337.
48. Kaiser M, Kuhnl A, Reins J, et al Antileukemic activity of the HSP70 inhibitor pifithrin-μ in acute leukemia. Blood Cancer J. 2011;1(7):e28.
49. Leu JI, Pimkina J, Pandey P, et al. HSP70 inhibition by the small-molecule 2-phenylethynesulfonamide impairs protein clearance pathways in tumor cells. Mol Cancer Res. 2011;9(7):936-947.
50. Fewell SW, Smith CM, Lyon MA, et al. Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity. J Biol Chem. 2004;279(49):51131-5140.
51. Braunstein MJ, Scott SS, Scott CM, et al. Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101. J Oncol. 2011;2011:232037.